{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:50:31Z","timestamp":1791424231871,"version":"4.3.3"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ymthe.2026.07.046","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:21:31Z","timestamp":1785338491000},"page":"5922-5944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of recombinant anti-TLR2 antibodies and PLGA nanoparticle-based gene therapy for the treatment of neuropathic pain"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8322-5797","authenticated-orcid":false,"given":"Subeen","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaekyung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellane Eda","family":"Barcelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpyo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-002X","authenticated-orcid":false,"given":"Sung Joong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.07.046_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2026.07.046_bib2","article-title":"Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank","volume":"8","author":"Baskozos","year":"2023","journal-title":"Pain Rep."},{"key":"10.1016\/j.ymthe.2026.07.046_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/2058738419838383","article-title":"The neuropathic pain: An overview of the current treatment and future therapeutic approaches","volume":"33","author":"Cavalli","year":"2019","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib4","series-title":"StatPearls","article-title":"Pain Management Medications. 2023","author":"Queremel Milani","year":"2026"},{"key":"10.1016\/j.ymthe.2026.07.046_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1347987","article-title":"The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets","volume":"16","author":"Adamu","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ymthe.2026.07.046_bib6","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1007\/s12035-016-0297-1","article-title":"Inflammatory Response in the CNS: Friend or Foe?","volume":"54","author":"Sochocka","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/342931","article-title":"Innate immunity and neuroinflammation","volume":"2013","author":"Shastri","year":"2013","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.ymthe.2026.07.046_bib8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.tips.2022.05.004","article-title":"Toll-like receptor-mediated neuroinflammation: relevance for cognitive dysfunctions","volume":"43","author":"Squillace","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2026.07.046_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fncel.2018.00329","article-title":"Role of Microglia TLRs in Neurodegeneration","volume":"12","author":"Fiebich","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ymthe.2026.07.046_bib10","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.4049\/jimmunol.175.7.4320","article-title":"TLR signaling tailors innate immune responses in human microglia and astrocytes","volume":"175","author":"Jack","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib11","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.1074\/jbc.M112.414904","article-title":"Toll-like receptor 2 mediates peripheral nerve injury-induced NADPH oxidase 2 expression in spinal cord microglia","volume":"288","author":"Lim","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.07.046_bib12","article-title":"The mechanism of microglia-mediated immune inflammation in ischemic stroke and the role of natural botanical components in regulating microglia: A review","volume":"13","author":"Zeng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib13","doi-asserted-by":"crossref","first-page":"14975","DOI":"10.1074\/jbc.M607277200","article-title":"A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity","volume":"282","author":"Kim","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.07.046_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib15","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3390\/microorganisms9091956","article-title":"A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies","volume":"9","author":"Silva-Pilipich","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ymthe.2026.07.046_bib16","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ymthe.2026.07.046_bib18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/nbt1126","article-title":"Selecting and screening recombinant antibody libraries","volume":"23","author":"Hoogenboom","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: An update","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2026.07.046_bib20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2026.07.046_bib21","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.07.046_bib22","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3390\/polym16182606","article-title":"Recent Applications of PLGA in Drug Delivery Systems","volume":"16","author":"Yang","year":"2024","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.ymthe.2026.07.046_bib23","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.ymthe.2026.07.046_bib24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17435889.2025.2487410","article-title":"PLGA nanoparticle-mediated anti-inflammatory gene delivery for the treatment of neuropathic pain","volume":"20","author":"Choi","year":"2025","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.ymthe.2026.07.046_bib25","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.16228","article-title":"NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies","volume":"5","author":"Moutel","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2026.07.046_bib26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/clpt.2013.150","article-title":"Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody","volume":"94","author":"Reilly","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2026.07.046_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116878","article-title":"Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells","volume":"10","author":"Haryadi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.07.046_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pep.2012.11.002","article-title":"Periplasmic production via the pET expression system of soluble, bioactive human growth hormone","volume":"87","author":"Sockolosky","year":"2013","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ymthe.2026.07.046_bib29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.nano.2019.02.023","article-title":"Foxp3 plasmid-encapsulated PLGA nanoparticles attenuate pain behavior in rats with spinal nerve ligation","volume":"18","author":"Shin","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ymthe.2026.07.046_bib30","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.intimp.2011.05.014","article-title":"The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response","volume":"11","author":"Nicolete","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113687","article-title":"The novel small-molecule antagonist MMG-11 preferentially inhibits TLR2\/1 signaling","volume":"171","author":"Grabowski","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib32","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1097\/j.pain.0000000000001902","article-title":"The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioids","volume":"161","author":"Speltz","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.ymthe.2026.07.046_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512464","article-title":"An Update on Toll-like Receptor 2, Its Function and Dimerization in Pro- and Anti-Inflammatory Processes","volume":"24","author":"Colleselli","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.07.046_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13041-022-00960-5","article-title":"Toll-like receptors and their role in neuropathic pain and migraine","volume":"15","author":"Liu","year":"2022","journal-title":"Mol. Brain"},{"key":"10.1016\/j.ymthe.2026.07.046_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.742065","article-title":"Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy","volume":"15","author":"Muzio","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymthe.2026.07.046_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/978-3-031-55529-9_22","article-title":"Microglia in Neuropathic Pain","volume":"37","author":"Inoue","year":"2024","journal-title":"Adv. Neurobiol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1744-8069-7-74","article-title":"Toll-like receptor 2 contributes to chemokine gene expression and macrophage infiltration in the dorsal root ganglia after peripheral nerve injury","volume":"7","author":"Kim","year":"2011","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ymthe.2026.07.046_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5238730","article-title":"Blockade of Toll-Like Receptors (TLR2, TLR4) Attenuates Pain and Potentiates Buprenorphine Analgesia in a Rat Neuropathic Pain Model","volume":"2016","author":"Jurga","year":"2016","journal-title":"Neural Plast."},{"key":"10.1016\/j.ymthe.2026.07.046_bib39","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1097\/j.pain.0000000000003275","article-title":"Diversity of microglial transcriptional responses during opioid exposure and neuropathic pain","volume":"165","author":"Sypek","year":"2024","journal-title":"Pain"},{"key":"10.1016\/j.ymthe.2026.07.046_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neulet.2013.08.062","article-title":"Up-regulation of spinal microglial Iba-1 expression persists after resolution of neuropathic pain hypersensitivity","volume":"554","author":"Leinders","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymthe.2026.07.046_bib41","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.celrep.2016.06.018","article-title":"Spinal Microgliosis Due to Resident Microglial Proliferation Is Required for Pain Hypersensitivity after Peripheral Nerve Injury","volume":"16","author":"Gu","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.07.046_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073640","article-title":"Neuropathic pain in rats with a partial sciatic nerve ligation is alleviated by intravenous injection of monoclonal antibody to high mobility group box-1","volume":"8","author":"Nakamura","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.07.046_bib43","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/ndt\/gfi316","article-title":"Leptospiral membrane proteins stimulate pro-inflammatory chemokines secretion by renal tubule epithelial cells through toll-like receptor 2 and p38 mitogen activated protein kinase","volume":"21","author":"Hung","year":"2006","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.ymthe.2026.07.046_bib44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4049\/jimmunol.1201644","article-title":"Complete dependence on IRAK4 kinase activity in TLR2, but not TLR4, signaling pathways underlies decreased cytokine production and increased susceptibility to Streptococcus pneumoniae infection in IRAK4 kinase-inactive mice","volume":"190","author":"Pennini","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib45","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.4049\/jimmunol.181.6.3841","article-title":"TLR2 expression in astrocytes is induced by TNF-alpha- and NF-kappa B-dependent pathways","volume":"181","author":"Phulwani","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.046_bib46","doi-asserted-by":"crossref","first-page":"13798","DOI":"10.1073\/pnas.0702553104","article-title":"Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits","volume":"104","author":"Tang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.07.046_bib47","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.celrep.2015.09.044","article-title":"Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy","volume":"13","author":"Kim","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.07.046_bib48","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41467-026-68870-x","article-title":"Anti-TLR2 immunotherapy modulates neuron-to-oligodendrocyte propagation of alpha-synuclein in mouse and human models","volume":"17","author":"Bae","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.07.046_bib49","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm0996-1028","article-title":"A humanized system for pharmacologic control of gene expression","volume":"2","author":"Rivera","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.07.046_bib50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1566523216666160524144041","article-title":"Tet-On Systems For Doxycycline-inducible Gene Expression","volume":"16","author":"Das","year":"2016","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.07.046_bib51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cell.2014.11.052","article-title":"Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds","volume":"160","author":"Zalatan","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.07.046_bib52","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.ymthe.2026.07.046_bib53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fnins.2019.00213","article-title":"Brain Microglial Activation in Chronic Pain-Associated Affective Disorder","volume":"13","author":"Barcelon","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymthe.2026.07.046_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5020","article-title":"The related mechanism of complete Freund's adjuvant-induced chronic inflammation pain based on metabolomics analysis","volume":"35","author":"Zhang","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ymthe.2026.07.046_bib55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/pharmaceutics13020180","article-title":"Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles","volume":"13","author":"Rojas-Prats","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2026.07.046_bib56","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.pain.2014.05.021","article-title":"Inflammatory and neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels","volume":"155","author":"Young","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.ymthe.2026.07.046_bib57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J. Neurosci. Methods"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626006672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626006672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:58:37Z","timestamp":1791421117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626006672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1525001626006672"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.07.046","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of recombinant anti-TLR2 antibodies and PLGA nanoparticle-based gene therapy for the treatment of neuropathic pain","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.07.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}